Erytasha Mahdy Pratama, NIM011511133212 (2018) PROFIL RESISTENSI ANTIRETROVIRAL PADA PASIEN HIV/AIDS DI RSUD Dr. SOETOMO SURABAYA. Skripsi thesis, Universitas Airlangga.

	Text (Abstrak) FK.PD. 45-19 Pra p Abstrak.pdf Download (107kB)
	Text (Daftar Isi) FK.PD. 45-19 Pra p Daftar Isi.pdf Download (111kB)
	Text (Daftar Pustaka) FK.PD. 45-19 Pra p Daftar Pustaka.pdf Download (122kB)
	Text (Fulltext) FK.PD. 45-19 Pra p.pdf Restricted to Registered users only until 9 July 2022. Download (1MB) | Request a copy

Abstract

Background: Dr. Soetomo Surabaya general hospital is a referral hospitals in the eastern part of Indonesia. Many HIV/AIDS patients were treated in hospital, so it needs to investigated the profile of ARV resistance. Objectives: The objective of this study was to identify the profile of ARV resistance in treated patients in Dr. Soetomo general hospital. Method: This study was using descriptive – retrospective design. The data of the profile ARV resistance was obtained for treated patients by using medical record. Result: Lamivudine and Nevirapine most often used, the most combination given was Lamivudine + Zidovudine + Nevirapine, the most resistant in Nevirapine and Efavirenz, based on the polymerase region mutase pattern of the NNRTI drug group was in Nevirapine (Y181C 50%) and Efavirenz (V106M 20%) while the NRTI group was in Lamivudine (M184V 12%) and Tenofovir (K65R 6%). Conclusion: Most patients have resistance to Nevirapine and Efavirenz, NNRTI groups on Nevirapine drugs obtained a Y181C, V108I, V106I, G190GA mutation of 47%, whereas in Efavirenz Y181C, V108I, V106I mutations were 41.2%. And from the NRTI group on the Lamivudine drug M184V was obtained, K65R was 29.4%, the Emitricitabine drug was M184V, K65R was 29.4%, Tenofovir was K65R was 11.8%, and Zidovudine was K219QE of 5.9%.

Actions (login required)

View Item